Howard Capital Management Inc. Has $416,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Howard Capital Management Inc. grew its position in Moderna, Inc. (NASDAQ:MRNA) by 3.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 9,994 shares of the company’s stock after purchasing an additional 297 shares during the period. Howard Capital Management Inc.’s holdings in Moderna were worth $416,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB boosted its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna during the 4th quarter valued at about $37,000. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on MRNA shares. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Finally, Morgan Stanley decreased their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Stock Down 4.6 %

Shares of NASDAQ:MRNA opened at $33.90 on Tuesday. The firm has a market cap of $13.05 billion, a price-to-earnings ratio of -3.65 and a beta of 1.59. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company’s fifty day simple moving average is $37.89 and its 200 day simple moving average is $52.10.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.